R.L. Siegel, K.D. Miller, H.E. Fuchs, A. Jemal, Cancer statistics, 2021. CA Cancer J. Clin. 71, 7–33 (2021)

Article  PubMed  Google Scholar 

D. Van Nostrand, Selected controversies of radioiodine imaging and therapy in differentiated thyroid cancer. Endocrinol. Metab. Clin. N. Am. 46, 783–793 (2017)

Article  Google Scholar 

C.M. Kitahara, J.A. Sosa, The changing incidence of thyroid cancer. Nat. Rev. Endocrinol. 12, 646–653 (2016)

Article  PubMed  PubMed Central  Google Scholar 

B.R. Haugen, E.K. Alexander, K.C. Bible et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26, 1–133 (2016)

Article  PubMed  PubMed Central  Google Scholar 

R.M. Tuttle, S. Ahuja, A.M. Avram et al. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid 29, 461–470 (2019)

Article  PubMed  Google Scholar 

M.E. Juweid, M. Tulchinsky, A. Mismar et al. Contemporary considerations in adjuvant radioiodine treatment of adults with differentiated thyroid cancer. Int. J. Cancer 147, 2345–2354 (2020)

Article  PubMed  CAS  Google Scholar 

L. Cheng, R. Sa, Q. Luo et al. Unexplained hyperthyroglobulinemia in differentiated thyroid cancer patients as an indication for radioiodine adjuvant therapy: a prospective multicenter study. J. Nucl. Med. 62, 62–68 (2021)

Article  PubMed  CAS  Google Scholar 

American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, D.S. Cooper, G.M. Doherty, B.R. Haugen et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214 (2009)

Article  Google Scholar 

F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, J.W.A. Smit, W. Wiersinga, The European Thyroid Cancer Taskforce, European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol. 154, 787–803 (2006).

Article  PubMed  CAS  Google Scholar 

P. Perros, K. Boelaert, S. Colley, British Thyroid Association et al. Guidelines for the management of thyroid cancer. Clin. Endocrinol. 81(Suppl 1), 1–122 (2014).

Article  CAS  Google Scholar 

T. Tian, R. Huang, B. Liu, Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment? Endocrine 65, 149–154 (2019)

Article  PubMed  CAS  Google Scholar 

T. Tian, Y. Xu, X. Zhang, B. Liu, Prognostic implications of preablation stimulated Tg: a retrospective analysis of 2500 thyroid cancer patients. J. Clin. Endocrinol. Metab. 106, e4688–e4697 (2021)

Article  PubMed  Google Scholar 

M. Schlumberger, G. Berg, O. Cohen et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur. J. Endocrinol. 150, 105–112 (2004)

Article  PubMed  CAS  Google Scholar 

M. Schlumberger, B. Catargi, I. Borget et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N. Engl. J. Med. 366, 1663–1673 (2012)

Article  PubMed  CAS  Google Scholar 

U. Mallick, C. Harmer, B. Yap et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N. Engl. J. Med. 366, 1674–1685 (2012)

Article  PubMed  CAS  Google Scholar 

M. Klain, E. Zampella, L. Piscopo et al. Long-term prognostic value of the response to therapy assessed by laboratory and imaging findings in patients with differentiated thyroid cancer. Cancers 13, 4338 (2021)

Article  PubMed  PubMed Central  CAS  Google Scholar 

M. Schlumberger, S. Leboulleux, B. Catargi et al. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. Lancet Diab. Endocrinol. 6, 618–626 (2018)

Article  Google Scholar 

Y. Iizuka, T. Katagiri, K. Ogura et al. Recurrence-free survival and prognosis after adjuvant therapy with radioactive iodine-131 in patients with differentiated thyroid carcinoma. Sci. Rep. 13, 10795 (2023)

Article  PubMed  PubMed Central  CAS  Google Scholar 

M. Klain, E. Zampella, M. Manganelli et al. Risk of structural persistent disease in pediatric patients with low or intermediate risk differentiated thyroid cancer. Endocrine 71, 378 (2021)

Article  PubMed  CAS  Google Scholar 

E. Zampella, L. Piscopo, M. Manganelli et al. Prognostic value of 12-month response to therapy in pediatric patients with differentiated thyroid cancer. Endocrine 80, 612 (2023)

Article  PubMed  PubMed Central  CAS  Google Scholar 

F.A. Verburg, B. De Keizer, C.J.M. Lips, P.M.J. Zelissen, J.M.H. De Klerk, Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. Eur. J. Endocrinol. 152, 33–37 (2005)

Article  PubMed  CAS  Google Scholar